The oligomeric state of thyroid receptor regulates hormone binding kinetics

Journal of Endocrinology

Volumn 210, Issue 1, 2011, Pages 125-134

  Cunha Lima, Suzana T ^a,b   Rodrigues, Edson D ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c Centro Universitario da Bahía   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOID X RECEPTOR; THYROID HORMONE RECEPTOR; THYROXINE I 125;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING KINETICS; GENE EXPRESSION; GENE MUTATION; HORMONE BINDING; LIGAND BINDING; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; CO-REPRESSOR PROTEINS; DIMERIZATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; IODINE RADIOISOTOPES; KINETICS; LIGANDS; MUTANT PROTEINS; PEPTIDE FRAGMENTS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; RECOMBINANT PROTEINS; RETINOID X RECEPTOR ALPHA; SURFACE PROPERTIES; THYROID HORMONE RECEPTORS ALPHA; THYROID HORMONE RECEPTORS BETA; TRIIODOTHYRONINE; ULTRACENTRIFUGATION;

EID: 79960299112     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0019     Document Type: Article

References (40)

1. Baxter JD &Webb P. 2009 Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nature Reviews. Drug Discovery 8 308-320.
2. Bleicher L, Aparicio R, Nunes FM, Martinez L, Gomes Dias SM, Figueira AC, Santos MA, Venturelli WH, da Silva R, Donate PM, et al.. 2008 Structural basis of GC-1 selectivity for thyroid hormone receptor isoformas. BMC Structural Biology 8 1-13.
3. Carlson KE, Choi I, Gee A, Katzenellenbogen BS & Katzenellenbogen JA. 1997 Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 36 14897-14905.
4. Cunha Lima ST, Nguyen NH, Togashi M, Apriletti J, Nguyen P, Polikarpov I, Scanlan TS, Baxter JD & Webb P. 2009 Differential effects of TR ligands on hormone dissociation rates: evidence for multiple ligand entry/exit pathways. Journal of Steroid Biochemistry and Molecular Biology 117 125-131.
5. Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, Fletterick RJ & Yamamoto KR. 1998 Structure and specificity of nuclear receptor-coactivator interactions. Genes and Development 12 3343-3356.
6. Feng W, Ribeiro RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, Baxter JD, Kushner PJ & West BL. 1998 Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280 1747-1749.
7. Figueira AC, Neto Mde O, Bernardes A, Dias SM, Craievich AF, Baxter JD, Webb P & Polikarpov I. 2007 Low-resolution structures of thyroid hormone receptor dimers and tetramers in solution. Biochemistry 46 1273-1283.
8. Figueira AC, Saidemberg DM, Souza PC, Marti{dotless}́nez L, Scanlan TS, Baxter JD, Skaf MS, Palma MS, Webb P & Polikarpov I. 2011 Analysis of agonist and antagonist effects on thyroid hormone receptor conformation by hydrogen/deuterium exchange. Molecular Endocrinology 25 15-31.
9. Glass CK & Rosenfeld MG. 2000 The coregulator exchange in transcriptional functions of nuclear receptors. Genes and Development 14 121-141.
10. Hu X & Lazar MA. 1999 The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402 93-96.
11. Huber BR, Desclozeaux M, West BL, Cunha Lima ST, Nguyen HT, Baxter JD, Ingraham HA & Fletterick RJ. 2003a Thyroid hormone receptor-beta mutations conferring hormone resistance and reduced corepressor release exhibit decreased stability in the N-terminal ligand-binding domain. Molecular Endocrinology 17 107-116.
12. Huber BR, Sandler B, West BL, Cunha Lima ST, Nguyen HT, Apriletti JW, Baxter JD & Fletterick RJ. 2003b Two resistance to thyroid hormone mutants with impaired hormone binding. Molecular Endocrinology 17 643-652.
13. Jeyakumar M, Webb P, Baxter JD, Scanlan TS & Katzenellenbogen JA. 2008 Quantification of ligand-regulated nuclear receptor corepressor and coactivator binding, key interactions determining ligand potency and efficacy for the thyroid hormone receptor. Biochemistry 47 7465-7476.
14. Jouravel N, Sablin E, Togashi M, Baxter JD, Webb P & Fletterick RJ. 2009 Molecular basis for dimer formation of TRbeta variant D355R. Proteins 75 111-117.
15. Laudet V & Gronemeyer H. 2002. The Nuclear Receptor Facts Book. Factsbook Series. edn 1, pp 462. London: Academic Press.
16. Marimuthu A, Feng W, Tagami T, Nguyen H, Jameson JL, Fletterick RJ, Baxter JD &West BL. 2002 TR surfaces and conformations required to bind nuclear receptor corepressor. Molecular Endocrinology 16 271-286.
17. Martinez L, Sonoda MT, Webb P, Baxter JD, Skaf MS & Polikarpov I. 2005 Molecular dynamics simulations reveal multiple pathways of ligand dissociation from thyroid hormone receptors. Biophysical Journal 89. 2011-2023.
18. Martinez L, Webb P, Polikarpov I & Skaf MS. 2006 Molecular dynamics simulations of ligand dissociation fromthyroid hormone receptors: evidence of the likeliest escape pathway and its implications for the design of novel ligands. Journal of Medicinal Chemistry 49 23-26.
19. Moore TW, Mayne CG & Katzenellenbogen JA. 2010 Minireview: not picking pockets: nuclear receptor alternate-site modulators (NRAMs). Molecular Endocrinology 24 83-695.
20. Motulsky H & Christopoulos A. 2003 Fitting models to biological data using linear and nonlinear regression. A practical guide to curve fitting. edn 4, pp 351. Oxford University ress.
21. Nettles KW & Greene GL. 2005 Ligand control of coregulator recruitment to nuclear receptors. Annual Review of Physiology 67 309-333.
22. Nguyen NH, Apriletti JW, Cunha Lima ST, Webb P, Baxter JD & Scanlan TS. 2002 Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. Journal of Medicinal Chemistry 45 3310-3320.
23. Nguyen NH, Apriletti JW, Baxter JD & Scanlan TS. 2005 Hammett analysis of selective thyroid hormone receptor modulators reveals structural and electronic requirements for hormone antagonists. Journal of the American Chemical Society 127 4599-4608.
24. Pissios P, Tzameli I, Kushner P & Moore DD. 2000 Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding. Molecular Cell 6 45-253.
25. Ribeiro RC, Feng W, Wagner RL, Costa CH, Pereira AC, Apriletti JW, Fletterick RJ & Baxter JD. 2001 Definition of the surface in the thyroid hormone receptor ligand binding domain for association as homodimers and heterodimers with retinoid X receptor. Journal of Biological Chemistry 276 14987-14995.
26. Sandler B, Webb P, Apriletti JW, Huber BR, Togashi M, Cunha Lima ST, Juric S, Nilsson S, Wagner R, Fletterick RJ, et al.. 2004 Thyroxine-thyroid hormone receptor interactions. Journal of Biological Chemistry 279 55801-55808.
27. Schueler PA, Schwartz HL, Strait KA, Mariash CN & Oppenheimer JH. 1990 Binding of 3,5,30-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: differences in the affinity of the alpha-and beta-forms for the acetic acid analog and failure of the human testis and kidney alpha-2 products to bind T3. Molecular Endocrinology 4 227-234.
28. Shulman AI, Larson C, Mangelsdorf DJ & Ranganathan R. 2004 Structural determinants of allosteric ligand activation in RXR heterodimers. Cell 116 417-429.
29. Sonoda MT, Martinez L, Webb P, Skaf MS & Polikarpov I. 2008 Ligand dissociation from estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations. Molecular Endocrinology 22 1565-1578.
30. Suthers MB, Pressley LA & Funder JW. 1976 Glucocorticoid receptors: evidence for a second, non-glucocorticoid binding site. Endocrinology 99 260-269.
31. Tamrazi A, Carlson KE, Daniels JR, Hurth KM & Katzenellenbogen JA. 2002 Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate. Molecular Endocrinology 16 2706-2719.
32. Togashi M, Borngraeber S, Sandler B, Fletterick RJ, Webb P & Baxter JD. 2005a Conformational adaptation of nuclear receptor ligand binding domains to agonists: potential for novel approaches to ligand design. Journal of Steroid Biochemistry and Molecular Biology 93 123-137.
33. Togashi M, Nguyen P, Fletterick R, Baxter JD & Webb P. 2005b Rearrangements in thyroid hormone receptor charge clusters that stabilize bound 3,5′,5-triiodo-L-thyronine and inhibit homodimer formation. Journal of Biological Chemistry 280 25665-25673.
34. Velasco LF, Togashi M, Walfish PG, PessanhaRP, Moura FN, Barra GB, Nguyen P, Rebong R, Yuan C, Simeoni LA, et al.. 2007 Thyroid hormone response element organization dictates the composition of active receptor. Journal of Biological Chemistry 282 12458-12466.
35. Wagner RL, Huber BR, Shiau AK, Kelly A, Cunha Lima ST, Scanlan TS, Apriletti JW, Baxter JD, West BL & Fletterick RJ. 2001 Hormone selectivity in thyroid hormone receptors. Molecular Endocrinology 15 398-410.
36. Webb P, Anderson CM, Valentine C, Nguyen P, Marimuthu A, West BL, Baxter JD & Kushner PJ. 2000 The nuclear receptor corepressor (N-CoR) contains three isoleucine motifs (I/LXXII) that serve as receptor interaction domains (IDs). Molecular Endocrinology 14. 1976-1985.
37. Webb P, Nguyen NH, Chiellini G, Yoshihara HA, Cunha Lima ST, Aprilett JW, Ribeiro RC, Marimuthu A, West BL, Goede P, et al.. 2002 Design of thyroid hormone receptor antagonists from first principles. Journal of Steroid Biochemistry and Molecular Biology 83 59-73.
38. Williams GR, Harney JW, Moore DD, Larsen PR & Brent GA. 1992 Differential capacity of wild type promoter elements for binding and trans-activation by retinoic acid and thyroid hormone receptors. Molecular Endocrinology 6 1527-1537.
39. Yen PM. 2001 Physiological and molecular basis of thyroid hormone action. Physiological Reviews 81 1097-1142.
40. Zhong L & Skafar DF. 2002 Mutations of tyrosine 537 in the human estrogen receptor-alpha selectively alter the receptor's affinity for estradiol and the kinetics of the interaction. Biochemistry 41 4209-4217.